Navigation Links
Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study

th migraine. An innovative, two-stage, adaptive dose-ranging design formulated through computer simulation was used to facilitate optimal dose selection.

A total of 420 adult patients who experienced migraine attacks, as defined by the International Headache Society criteria, were randomized (330 took drug) to treat a moderate or severe migraine attack with MK-0974 given orally at doses of 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, or 600 mg, or rizatriptan 10 mg, or placebo. Patients enrolled were primarily female (89 percent) with an average age of 41 years. Most treated headaches were moderate in baseline severity and did not have aura.

The first stage of the study evaluated all doses of MK-0974 with rizatriptan and placebo. When a preset number of migraine attacks were treated, an interim efficacy analysis was conducted resulting in dropping the four lowest doses of MK-0974 based on a pre-specified algorithm. The second stage of the study continued with randomization of patients to MK-0974 300 mg, 400 mg or 600 mg or to rizatriptan 10 mg or placebo.

Overall treatment effect was analyzed by comparing the average response of the MK-0974 treatment groups (300 mg, 400 mg and 600 mg) to the response observed in the placebo group. The study was not powered to detect differences between the individual doses of MK-0974 or between MK-0974 doses and rizatriptan.

Study results

For the primary endpoint, the overall treatment effect of MK-0974 in relieving migraine pain (reduction from severe or moderate to mild or none) two hours after dosing was significant compared to placebo (p=0.015). The proportion of patients reporting pain relief at two hours for those treated with MK-0974 was 68.1 percent (300 mg; n=38), 48.2 percent (400 mg; n=45) and 67.5 percent (600 mg, n=40); and 69.5 percent for rizatriptan (n=34) compared to 46.3 percent for placebo (n=115).

A similar pattern was observed for secondary measures in which the overall
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
4. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
5. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:8/28/2015)... , Aug. 28, 2015  CytomX Therapeutics, Inc., a ... cancer, today announced the filing of a registration statement ... Commission (SEC) relating to a proposed initial public offering ... be offered and the price range for the offering ... its common stock under the symbol "CTMX" on the ...
(Date:8/28/2015)... 28, 2015 Research ... addition of the "12th Annual Report and ... report to their offering. The 2015 ... Capacity and Production is the most recent study ... and projected future capacity and production. The report ...
(Date:8/28/2015)... Research and Markets ... the "Investigation Report on China,s Quetiapine Market, ... Developed by AstraZeneca plc, quetiapine (under the trade ... the treatment of schizophrenia. Approved by CFDA to ... the Catalogue of Drugs for the Basic National ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Quetiapine Market Investigation Report 2010-2019 2
... COMBINATION WITH DIURETIC ACCEPTED FOR REVIEW BY,FDA- , ... 2007 -,Speedel (SWX: SPPN) today welcomed the significant ... by investigators at the 22nd Annual Scientific Meeting,and ... in,Chicago, IL, USA. These results confirm the favourable ...
... inflammation in models of,arthritis and Salmonella infection, ... -, WASHINGTON, May 21, 2007 /PRNewswire/ -- ... from two studies,that demonstrate the anti-inflammatory activity ... origin, Bifantis(R),(Bifidobacterium infantis 35624), in models of ...
Cached Medicine Technology:New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 2New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 3New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 4New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 5New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 6New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 7New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 8New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 9New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 10New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 11New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory,Properties and Increased Health Benefits 2New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory,Properties and Increased Health Benefits 3
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, 2015 , ... ... and InHealth Media. Nutritional Products International and InHealth media is a global sales ... , “We are extremely pleased to continue our business relationship with Mr. Reid ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... devices for the treatment of prostate cancer, has announced the roll-out of its ... the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently in ...
(Date:8/29/2015)... ... August 30, 2015 , ... Electronic Informed Consent for ... 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact about electronic informed ... , Clinical trial sites can now use audio, video and interactivity to ...
(Date:8/29/2015)... ... August 29, 2015 , ... It ... and protection against dribbled urine and sweat. "In order to prevent these problems, ... The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT provides optimal support for a male’s ...
(Date:8/29/2015)... ... ... like Toppik , Eau Thermale Avene and Bliss are now available on ... required to qualify for free standard shipping,” said Jennifer Ramirez, the public relations manager. ... the item’s selling price.” , With competitive pricing in the e-commerce market for beauty ...
Breaking Medicine News(10 mins):Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
... Leicester and the University of Ferrara in Italy have collaborated ... cancer pain without causing many of the side effects of ... 90% of cancer patients experience pain in the final year ... the use of drugs like morphine produces side effects such ...
... appendicitis are often diffuse and it can be difficult to ... disease. It may be possible to predict the severity from ... on an individual basis. This is the conclusion of a ... know what causes appendicitis. There is evidence that the cause ...
... didn,t accurately diagnose elderly Asians, study found , MONDAY, ... year by the American Diabetes Association as an effective ... of Singapore suggests that the hemoglobin A1c blood test ... , The American Diabetes Association,s current recommendation is that ...
... ... well as the degree programs, you don,t need to look too far. A comprehensive guide ... useful awaits you at EducationCenters.com. A stop shop for all your education needs, this site ... , ...
... Reza ... as Exclusive Distributor/Manufacturer for Saudi Arabia and the Middle East, , ... Newark, NJ (PRWEB) June 21, 2010 -- BioNeutral Group ... Chief Scientist, Dr. Andy Kielbania, will assist with a similar role in Steri – 7, ...
... ... Enterprise Mobile Management drives down support costs, improves performance and service quality of mobility ... has made available a complimentary copy of the report in the link below. ... (PRWEB) June 21, ...
Cached Medicine News:Health News:New drugs to relieve cancer pain 2Health News:New possibility to determine the severity of appendicitis 2Health News:Age, Race May Affect Type 2 Diabetes Screening Results 2Health News:The Epicenter of Education Information is Not Too Far Away 2Health News:BioNeutral Chief Scientist Dr. Andy Kielbania Appointed to Steri - 7 for Expanded Role 2Health News:BioNeutral Chief Scientist Dr. Andy Kielbania Appointed to Steri - 7 for Expanded Role 3Health News:BioNeutral Chief Scientist Dr. Andy Kielbania Appointed to Steri - 7 for Expanded Role 4Health News:Industry Benchmark Report Finds Full Mobile Lifecycle Management and ITSM Critical to Enterprise Mobile Management 2Health News:Industry Benchmark Report Finds Full Mobile Lifecycle Management and ITSM Critical to Enterprise Mobile Management 3Health News:Industry Benchmark Report Finds Full Mobile Lifecycle Management and ITSM Critical to Enterprise Mobile Management 4
... The Videoscopes provide superior image ... connecting to the camera head with ... density ensures more light at the ... provide optimum image clarity and reliability.,The ...
... Passport II delivery device is the second ... C11UB. Its simple-to-use syringe technology allows one-handed ... small incision. The blue colored plunger allows ... protect the haptics during insertion. The modified ...
... for long-term transtelephonic monitoring. Simple to use, ... in order to record all pre and post ... button, the patient sends the recorded ECG over ... for immediate diagnosis. Use of Heart 2005A is ...
... IMPACs comprehensive information system designed specifically ... integrate and streamline their diagnostic, management, ... intuitive software solution. Thousands of laboratory ... have proven PowerPaths unique "case-centric model ...
Medicine Products: